



2500 Meadowpine Blvd.
Unit 202, Mississauga, ON L5N 6C4
Ph: (416) 669-9392
Email: ir@sirebioscience.com
www.sirebioscience.com

**Sire Bioscience Inc. Announces Application for a Management Cease Trade Order
For Late Filing of Annual Audited Financial Statements**

MISSISSAUGA, Ontario, January 20, 2021 – Sire Bioscience Inc. (CSE:SIRE) (OTC:BLLXF) (FSE:BR1B) (“Sire” or the “Company”) announces it will be unable to file its annual audited financial statements, management’s discussion and analysis and related certifications for the year ended September 30, 2020 (the “**Annual Filings**”) on or before the prescribed filing deadline, as required by National Instrument 51-102 *Continuous Disclosure Obligations*, and National Instrument 52-109 *Certification of Disclosure in Issuers’ Annual and Interim Filings*, respectively. The Company anticipates that its auditor will need approximately 3 weeks to complete the audit of the Company’s annual financial statements.

The Company has filed an application with the Ontario Securities Commission, the British Columbia Securities Commission and the Alberta Securities Commission requesting issuance of a management cease trade order against the Company’s executive officers and directors instead of a cease trade order against the Company and all of its securityholders.

The Company anticipates that it will be in a position to file the Annual Filings on or before February 15, 2021. The Company confirms that it will comply with the alternative information guidelines included in National Policy 12-203 *Management Cease Trade Orders*, for so long as it remains in default of a specified requirement.

About Sire Bioscience Inc.

SIRE is headquartered in Mississauga, Ontario, and is managed by a group of successful entrepreneurs who have extensive experience in the areas of consumer packaged goods, manufacturing, logistics, and distribution. SIRE is currently exiting the cannabis industry and moving into the plant-based foods and supplements industry.

FOR INFORMATION, CONTACT:

Sire Bioscience Inc.

Brian Polla, CEO

T: 416.669.9392

E: ir@sirebioscience.com

W: sirebioscience.com

Socials: [@sirebioscience](https://www.instagram.com/sirebioscience)

The Canadian Securities Exchange (“CSE”) has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.